UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
June 28, 2019
Date of report (date of earliest event reported)
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Michigan |
| 000-23661 |
| 38-3317208 |
(State or other |
| (Commission File |
| (IRS Employer |
30142 Wixom Road, Wixom, Michigan 48393
(Address of principal executive offices, including zip code)
(248) 960-9009
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
| Trading Symbol |
| Name of each Exchange on which registered |
Common Stock, no par value |
| RMTI |
| Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01. Other Events
On June 28, 2019, Rockwell Medical, Inc. (the “Company”) executed an extension (the “Contract Extension”) of its Amended and Restated Products Purchase Agreement with DaVita Inc. (“DaVita”), dated May 8, 2013 (as subsequently amended, the “DaVita Purchase Agreement”). Pursuant to the Contact Extension, the term of the DaVita Purchase Agreement was extended through July 31, 2019. The purpose of the Contract Extension was to provide a continued product supply under the DaVita Purchase Agreement through July 31, 2019 while the Company and DaVita continue to negotiate and document a new long-term supply contract.
* * *